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j Abstract Objective The aim was to investigate the
hypothesis that patients with ﬁrst episode schizo-
phrenic disorders have a more favorable treatment
response than those with multiple episodes. Method A
total of 400 inpatients from an ongoing multi-centre,
follow-up program who fulﬁlled ICD-10 criteria for
schizophrenic disorders (F2) were assessed at admis-
sion to and discharge from hospital using the Positive
and Negative Syndrome Scale (PANSS). Results At
admission, ﬁrst episode patients (n = 121) showed
higher levels of positive symptoms (PANSS positive
subscore) and lower ones of negative symptoms
(PANSS negative subscore) than multiple episode pa-
tients (n = 279), whereas the global disease severity
(PANSS total score) was comparable. Analyses of
covariance revealed that treatment response (adjusted
symptom levels at discharge) was more favorable in
ﬁrst-episode patients, with respect to both positive
and negative symptoms. Conclusion The results are
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3compatible with the hypothesis that treatment re-
sponse becomes less favorable during the course of
schizophrenic illness. This ﬁnding might be associated
with progressive neurobiological alterations.
j Key words schizophrenic disorders Æ ﬁrst episode Æ
multiple episode Æ treatment response Æ PANSS
Introduction
In the past decade there has been increasing interest
in early stages of schizophrenic disorders. Numerous
studies have shown that a reduction of the duration of
untreated psychosis might be associated with a more
favorable treatment outcome [6, 25]. These ﬁndings
are the theoretical basis for early recognition and
intervention programs [15]. Furthermore, it seems to
be generally accepted that patients suffering from a
ﬁrst episode of a schizophrenic disorder tend to be
more responsive to antipsychotic treatment than
multiple episode patients [24]. These assumptions
have resulted in special recommendations for this
group in current treatment guidelines [4, 9, 23].
Indeed, there are several studies which indicate
that ﬁrst episode patients have a favorable treatment
response and require lower doses of antipsychotic
drugs than multiple episode patients to achieve
remission [10, 24]. However, original data comparing
ﬁrst episode with multiple episode schizophrenic
disorders with respect to the acute treatment response
are rare: Lieberman et al. [16] followed prospectively
for up to 5 years a sample of patients with ﬁrst epi-
sode schizophrenic disorders. This study found a
clear pattern of decreasing responsiveness to treat-
ment over subsequent episodes of illness in terms of
an increased time to remission [17]. Sanger et al. [26]
analyzed data from a large multi-centre, double-blind
study comparing olanzapine with haloperidol. First
episode patients treated with olanzapine showed a
greater improvement of psychopathological symp-
toms than multiple episode patients. However, only
slight differences between ﬁrst and multiple episode
patients were found in the haloperidol group.
Furthermore, it is unclear whether patients with
ﬁrst episode schizophrenic disorders display a speciﬁc
proﬁle of psychopathological symptoms and cognitive
impairment. Sanger et al. [26] reported less pro-
nounced negative symptoms in ﬁrst episode compared
with multiple episode patients. Other studies found an
increasing frequency of negative symptoms [5, 22] and
neuropsychological impairment [7] with a longer
duration of illness, which led to the hypothesis of a
‘‘neurodegenerative model’’ of schizophrenic disor-
ders [18]. On the other hand, further studies failed to
identify marked differences between ﬁrst episode and
chronic schizophrenic disorders with respect to psy-
chopathological symptoms [20, 27], neuropsycholog-
ical function [1, 21] or social deﬁcits [11]. These latter
results, which indicate that psychopathological and
neuropsychological disturbances are already present
in early and even premorbid stages of schizophrenic
disorder and remain stable in the further course of
illness, are more compatible with a ‘‘neurodevelop-
ment model’’, which hypotheses that schizophrenia
has its origin in the early development of the brain.
Taken together, conﬂicting results have been re-
ported about the clinical characteristics of ﬁrst epi-
sode schizophrenic disorders. The hypothesis of a
better treatment response in ﬁrst episode patients
needs further validation.
Based on a large sample of inpatients suffering
from schizophrenic disorders and treated under nat-
uralistic conditions, the present study examines dif-
ferences between ﬁrst episode and multiple episode
patients with respect to psychopathological charac-
teristics at admission and treatment response. The
main hypothesis was that ﬁrst episode patients show a
more favorable treatment response than multiple
episode patients.
Methods
j Subjects
The sample stems from a multi-centre follow-up program (German
Research Network on Schizophrenia) [30] conducted in 11 psy-
chiatric university hospitals (Aachen, Berlin, Bonn, Cologne, Du ¨s-
seldorf, Essen, Go ¨ttingen, Hamburg, Mainz, Munich, Tu ¨bingen)
and three psychiatric district hospitals (Augsburg, Gabersee, Haar).
Subjects were randomly selected from all consecutively admitted
patients suffering from schizophrenia and related disorders (ICD-
10: F20, F21, F22, F23, F24, F25, F28) who were admitted between
January 2001 and December 2004 to one of the 14 hospitals men-
tioned above. The selection process was carried out using ran-
domization software. Subjects were aged between 18 and 65 years.
Exclusion criteria were a history of major medical illness, head
injury or symptoms of drug or alcohol dependence.
Patients were treated under naturalistic conditions (e.g. phar-
macological treatment with antipsychotics, psychosocial treatment
like psychoeducation programs, social skill training or family
interventions). All patients had given informed, written consent to
participate in the study. The study protocol was approved by the
local ethics committees.
j Assessments
ICD-10 diagnoses (at time of admission) were based on clinical
information including interviews with patients, relatives and care
providers, according to ICD-10 research diagnostic criteria [29].
First episode disorder was deﬁned by ﬁrst hospitalization and ab-
sence of a prior episode of schizophrenic disorder. Duration of
illness was deﬁned as the time since the ﬁrst occurrence of any
psychopathological symptoms.
Global functioning was assessed using the Global Assessment of
Functioning Scale (GAF) [3]. Social parameters (partnership,
employment state) were assessed with the Strauss-Carpenter scale
[28]. Psychopathological characteristics were assessed with the
Positive and Negative Syndrome scale for Schizophrenia (PANSS)
[13], and the 17-item version of the Hamilton rating scale for
Depression (HAM-D) [12].
48Ratings were performed within the ﬁrst 3 days after admission,
and repeated at biweekly intervals during the acute inpatient
treatment phase as well as at discharge. All raters had been trained
for the instruments and a high inter-rater reliability was achieved
(ANOVA-ICC > 0.8).
j Statistical analyses
The hypothesis that ﬁrst episode patients show a more favorable
treatment response than multiple episode patients was examined
using an analysis of covariance (ANCOVA) with a type III sum
of squares based on a general linear model procedure. First
episode and multiple episode patients were compared with re-
spect to the PANSS total score at discharge from hospital as the
primary criterion for treatment outcome, adjusted for the PANSS
total score at admission as the confounding variable. Post-hoc
analyses were performed for PANSS positive subscore, PANSS
negative subscore, PANSS general psychopathology subscore,
HAM-D total score and GAF at discharge, adjusted for the
respective values at admission. Lower symptom levels and a
higher global functioning at discharge (adjusted for respective
values at admission) were taken to indicate a favorable treatment
response.
Differences with respect to sociodemographic variables, psy-
chopathological symptoms at admission and treatment character-
istics between ﬁrst episode and multiple episode patients were
evaluated using the t-test for continuous and the v
2-test for cate-
gorical variables. These tests were used in terms of an exploratory
analysis.
All statistical analyses were carried out using the SPSS 12.0
Software for Windows. For all statistical analyses a p-value
of £ 0.05 (2-tailed) was considered as statistically signiﬁcant.
Results
j Description of the sample
In total, 474 patients with schizophrenic disorders
(ICD-10: F2) were enrolled in the study. A total of 46
patients (10%) dropped out for different reasons (e.g.
withdrawal of informed consent, retrospective viola-
tion of inclusion criteria, incomplete information).
A further 28 patients (6%) were excluded from the
analysis because they were discharged from hospital
within seven days after admission. The present sam-
ple therefore comprised 400 subjects, 121 with ﬁrst
episode and 279 with multiple episode schizophrenic
disorders. Baseline characteristics are shown in
Table 1.
As expected, ﬁrst episode patients were younger
than multiple episode patients, showed a shorter
duration of illness and a higher social functioning in
terms of stable partnership and regular employment.
First episode patients were more often diagnosed with
acute and transient psychotic disorders (ICD-10: F23)
and less often with schizoaffective disorders (ICD-10:
F25). They were older than multiple episode patients
at the time of the occurrence of the ﬁrst symptoms
and at the time of ﬁrst hospitalization. No differences
were found with respect to gender and global func-
tioning (GAF) at admission.
j Psychopathological characteristics at admission of
first episode patients compared with multiple
episode patients
When both groups were compared with respect to
psychopathological symptoms at admission (Table 2),
signiﬁcant differences were found with respect to the
distribution of positive and negative symptoms: First
episode patients showed higher means in the PANSS
positive subscore and lower ones in the PANSS
negative subscores than multiple episode patients.
However, no signiﬁcant differences were found
with respect to the PANSS total score indicating a
comparable global severity of illness. The same was
Table 1 Patients characteristics
First episode
(n = 121)
Multiple episode
(n = 279)
Total
(n = 400)
p-level
b
Age 32.0 (10.8) 37.0 (10.9) 35.5 (11.1) T = )4.291, p < 0.001
Gender (female) 43.0% (n = 52) 43.7% (n = 122) 43.5% (n = 174) v
2 = 0.19, p = 0.889
Diagnoses (admission) v
2 = 26.191, p < 0.001
Schizophrenia (F20) 80.2% (n = 97) 81.0% (n = 226) 80.8% (n = 323)
ATPD
a (F23) 13.2% (n = 16) 2.9% (n = 8) 6.0% (n = 24)
Schizoaffective disorder (F25) 4.1% (n = 5) 15.1% (n = 42) 11.8% (n = 47)
Others (F21, F22, F24, F28) 2.5% (n = 3) 0.7% (n = 3) 1.6% (n =6 )
Course of illness
Age at first symptoms (years) 28.6 (12.4) 23.1 (0.1) 24.7 (11.1) T = 4.333, p < 0.001
Age at first hospitalization (years) 29.6 (12.5) 26.1 (10.6) 27.1 (11.3) T = 2.704, p < 0.001
Duration of illness (years) 3.3 (7.5) 13.9 (0.9) 10.7 (11.1) T = )11.2, p < 0.001
Social functioning
Stable partnership 28.1% (n = 34) 18.6% (n = 52) 21.5% (n = 86) v
2 = 4.476, p = 0.034
Regular employment 76.0% (n = 92) 41.9% (n = 117) 52.3% (n = 209) v
2 = 39.329, p < 0.001
Global Assessment of Functioning (GAF)
at admission
42.9 (12.3) 42.3 (11.8) 42.5 (11.9) T = 0.502, p = 0.616
Values are presented as means (±standard deviation)
a ATPD: Acute and transient psychotic disorders
b First episode patients were compared with multiple episode patients
49also true for the PANSS general psychopathology
subscore and the HAM-D score.
j Treatment response of first episode patients
compared with multiple episode patients
The PANSS total score at discharge was used as the
primary criterion for treatment response. The com-
parisons between ﬁrst episode patients and multiple
episode patients are shown in Fig. 1.
Both groups were compared using an ANCOVA
model with PANSS total score at discharge as the
dependent variable and PANSS total score at
admission as the covariate: The overall ANCOVA
was signiﬁcant (F = 89.176, df = 2, p < 0.001, ad-
justed R
2 = 0.307), suggesting that 31% of the vari-
ance could be explained with this model. Signiﬁcant
differences were found between ﬁrst episode and
multiple episode patients indicating a more favorable
treatment response in ﬁrst episode patients. p-levels
and means of PANSS total scores at discharge ad-
justed for respective levels at admission are shown in
Table 3.
Post hoc analyses (ANCOVA-model) revealed that
ﬁrst episode patients showed lower levels in the
PANSS positive subscore, the PANSS negative sub-
score and the PANSS general psychopathology sub-
score at discharge than multiple episode patients, too.
On the other hand, ﬁrst episode patients showed a
higher level of the Global Assessment of Functioning
(GAF) score at discharge than multiple episode pa-
tients. No signiﬁcant differences, however, were found
with respect to the total HAM-D score at discharge.
Symptom levels and global functioning at discharge
were adjusted for respective values at admission
(Table 3).
Treatment characteristics are shown in Table 4.N o
differences between ﬁrst episode and multiple episode
patients were found with respect to the duration of
hospitalization and the frequency of treatment with
tranquilizers, ﬁrst generation antipsychotics or sec-
ond generation antipsychotics. However, ﬁrst episode
patients were less often treated with antidepressant
drugs and mood stabilizers.
Table 2 Psychopathological
characteristics at admission First episode
(n = 121)
Multiple episode
(n = 279)
Total
(n = 400)
p-level
a
PANSS
Total score 69.6 (20.4) 72.0 (18.6) 71.3 (19.2) T = )1.123, p = 0.262
Positive symptoms 20.4 (6.3) 18.5 (6.3) 19.1 (6.4) T = 2.720, p = 0.007
Negative symptoms 15.6 (7.3) 18.4 (7.2) 17.6 (7.4) T = )3.582, p < 0.001
General psychopathology 33.7 (11.0) 35.0 (9.7) 34.6 (10.1) T = )1.253, p = 0.211
HAM-D total score 9.8 (6.4) 10.2 (7.6) 10.1 (7.3) T = )0.525, p = 0.600
Values are presented as means (±standard deviation)
a First episode patients were compared with multiple episode patients
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Fig. 1 Treatment response (unadjusted changes in PANSS total score) of first
episode compared with multiple episode schizophrenic disorders
Table 3 Adjusted levels of
psychopathological symptoms and
global functioning at discharge
First episode
(n = 121)
Multiple episode
(n = 279)
p-level
PANSS
Total score 45.1 (CI: 42.8–47.5) 52.7 (CI: 51.1–54.3) F = 28.542, df = 1, p < 0.001
Positive symptoms 9.1 (CI: 8.5–9.7) 11.1 (CI: 10.7–11.5) F = 26.249, df = 1, p < 0.001
Negative symptoms 13.5 (CI: 12.6–14.5) 15.0 (CI: 14.3–15.6) F = 6.030, df = 1, p = 0.014
General psychopathology 22.9 (CI: 21.7–24.1) 26.5 (CI: 25.7–27.3) F = 25.215, df = 1, p < 0.001
HAM-D total score 3.6 (CI: 2.8–4.4) 4.4 (CI: 3.9–4.9) F = 2.336, df = 1, p = 0.125
GAF 71.0 (CI: 69.0–73.0) 62.9 (CI: 61.6–64.2) F = 44.537, df = 1, p < 0.001
Values are presented as adjusted means for scores at admission and 95% confidence intervals in parenthesis
50Discussion
j Sample
Based on a sample of 400 inpatients suffering from
schizophrenic disorders (ICD-10: F2), the aim of the
present study was to compare ﬁrst episode (n = 121)
with multiple episode patients (n = 279) with respect
to sociodemographic and other clinical variables, psy-
chopathological symptoms and treatment response.
The sample was randomly selected from all patients
consecutively admitted to university or district hospi-
tals. In contrast to the study by Sanger et al. [26], pa-
tients in the present study did not have to fulﬁll the
strict inclusion criteria of a clinical double-blind trial.
Patients were treated under naturalistic conditions.
Differences between ﬁrst episode and multiple episode
patients were found with respect to the frequency of
treatment with antidepressant drugs and mood stabi-
lizer. Surprisingly, a high administration rate of ﬁrst
generation antipsychotics was found in both groups.
This ﬁnding may be explained by the fact that the
group of ﬁrst generation antipsychotics includes low
potency antipsychotics that are often used for the
treatment of agitation and sleep disturbances.
j Treatment response
The present study was able to conﬁrm the hypothesis
that ﬁrst episode patients have a more favorable
treatment response than multiple episode patients:
First-episode patients showed lower levels in PANSS
total scores at discharge (the primary outcome crite-
rion) than multiple episode patients. The same was
true for the PANSS subscores for positive symptoms,
negative symptoms and general psychopathology at
discharge. On the other hand, ﬁrst-episode patients
showed higher levels in the Global Assessment of
Functioning (GAF) score at discharge than multiple
episode patients. Statistical analyses were adjusted for
the respective scores at admission as confounding
variables (ANCOVA-model).
Similar results were reported by Sanger et al. [26],
who compared ﬁrst episode (n = 83) and multiple
episode patients (n = 1913) with respect to the reduc-
tion of psychopathological symptoms after 6 weeks
antipsychotic treatment with haloperidol or olanza-
pine. In this study, only ﬁrst episode patients treated
with olanzapine (n = 58) showed a greater improve-
ment in PANSS total scores than multiple episode pa-
tients of this group, whereas no signiﬁcant differences
werefoundbetweenﬁrstepisode(n = 24)andmultiple
episode patients in the haloperidol group. Further-
more, no signiﬁcant differences were found with re-
specttothechangesofPANSSnegativesubscoreseither
in the haloperidol or the olanzapine group. These
conﬂicting ﬁndings may result from a lower statistical
power, especiallyin the haloperidol group, and the fact
thattheanalyseswerenotadjustedforbaselinesscores.
The results of the present study, i.e. that ﬁrst epi-
sode patients show a more favorable treatment re-
sponse than multiple episode patients, are compatible
with the ﬁndings of Lieberman et al. [17] who fol-
lowed prospectively a sample of ﬁrst episode patients
and found a decreased responsiveness to treatment
over subsequent episodes in terms of an increased
time to remission. The present study failed to reveal
differences between ﬁrst episode and multiple episode
patients with respect to the duration of hospitaliza-
tion. In contrast to Lieberman et al. [17], however, the
time to remission was not addressed in the present
study, and the duration of hospitalization is not only
inﬂuenced by the time to remission.
j Psychopathological characteristics
Although the overall severity of schizophrenic
symptoms (PANSS total score) was comparable in
both groups, ﬁrst episode patients showed more
pronounced positive symptoms (PANSS positive
subscore) and less pronounced negative symptoms
(PANSS negative subscore) than multiple episode
patients at admission. With respect to depressive
symptoms, no signiﬁcant differences were found be-
tween the two groups at admission.
These ﬁndings are in line with those of Sanger et al.
[26], who also reported lower means of PANSS nega-
tive subscores in ﬁrst episode patients before anti-
Table 4 Treatment characteristics
First episode
(n = 121)
Multiple episode
(n = 279)
Total
(n = 400)
p-level
a
Duration of hospitalization (days) 53.7 (39.1) 53.4 (47.0) 53.5 (44.7) T = 0.048, p = 0.962
Medication
b
First generation antipsychotics 69.4% (n = 84) 63.8% (n = 178) 65.5% (n = 262) v
2 = 1.181, p = 0.277
Second generation antipsychotics 46.3% (n = 56) 52.7% (n = 147) 50.8% (n = 203) v
2 = 1.386, p = 0.239
Antidepressants 11.6% (n = 14) 23.3% (n = 65) 19.8% (n = 79) v
2 = 7.323, p = 0.007
Tranquilizers 57.9% (n = 70) 50.9% (n = 142) 53.0% (n = 212) v
2 = 1.639, p = 0.200
Mood stabilizers 5.8% (n = 7) 14.3% (n = 40) 11.8% (n = 47) v
2 = 5.952, p = 0.015
Values are presented as means (±standard deviation)
a First episode patients were compared with multiple episode patients
b Multiple entries are possible. The duration of application of these drugs during the whole inpatient treatment period is not mentioned in this presentation
51psychotic treatment. The results are also compatible
with those of Murphy et al. [22] and Bottlender et al.
[5], who found an increasing frequency of negative
symptomswithalongerdurationofillness.Conﬂicting
results, however, have been reported by Shtasel et al.
[27], who compared 37 ﬁrst episode patients with 70
chronic schizophrenic patients and found no marked
differences in the psychopathological symptom pro-
ﬁle, and especially no differences with respect to neg-
ative symptoms. However, these results are limited by
the small sample size. The same is true for the study by
Moritz et al. [20] who compared 20 ﬁrst episode pa-
tientswith36chronicpatientsandfoundacomparable
psychopathological proﬁle for both groups.
j Disease progression in schizophrenic disorders or
sampling effect?
The ﬁndings that multiple episode patients have more
pronounced negative symptoms and a less favorable
treatment response than ﬁrst episode patients are
compatible with the model of a progressive and
deteriorating illness [5, 18], which derives from
Kraepelin’s original concept of ‘‘dementia praecox’’
[14]. The progressive course might be associated with
neurobiological alterations. However, this concept
may apply only to a subgroup of patients with
schizophrenic disorders.
These conclusions, however, should be regarded
withcaution.Onehastoconsiderthattheresultsofthe
present cross-sectional study could reﬂect a sampling
biasbecausepatientswithaninitiallymoreunfavorable
course of illness have a higher likelihood of further
hospitalizations, regardless of whether there is a pro-
gressive course or not. In this context, one has to note
that ﬁrst episode patients were older than multiple
episodepatientsatthetimeoftheoccurrenceoftheﬁrst
symptoms and at the time of ﬁrst hospitalization.
Similar results indicating an earlier onset of illness in
thegroupofmultipleepisodepatientswerereportedby
previous studies [2, 26, 27] although these surprising
ﬁndings were not discussed in detail. Other studies,
however, revealed that patients with an early onset of
schizophrenic disorders show a poorer response to
antipsychotic treatment [19] and a higher risk for fur-
therhospitalization[8],whichmightexplaintheresults
mentioned above in terms of a sampling effect.
j Limitations
The present analysis is limited by its cross-sectional
design, so that conclusions about the concept of dis-
ease progression should be made with caution
because the results could reﬂect a sampling bias.
Furthermore, one has to consider that symptom
levels and global functioning at discharge from hos-
pital were used as criterion for treatment response.
Follow-up examinations were not included in the
present study. Therefore, the present analyses are
limited to the acute treatment response during the
inpatient treatment period.
Moreover, the aim of the present study was to
examine an unselected and representative sample of
patients routinely treated in a psychiatric hospital.
Patients were treated under naturalistic conditions
and effects of medication were not controlled. There-
fore, the results could be confounded by potential
treatment differences between ﬁrst episode and mul-
tiple episode patients. Particularly, this may be true for
the early course of illness, because systems of care and
treatment guidelines have chanced substantially in the
past decades.
Finally, one should note that the sample was not
limited to patients suffering from schizophrenia, but
also included patients with delusional, acute and
transient psychotic disorders and schizoaffective dis-
orders in terms of schizophrenic spectrum disorders.
j Conclusions
The present study was able to conﬁrm the hypothesis
that patients with ﬁrst episode schizophrenic disor-
ders have a more favorable treatment response than
multiple episode patients. The results can be inter-
preted in terms of a model which considers schizo-
phrenia or a subtype of schizophrenic disorders as a
progressive illness. The decrease of treatment re-
sponse in multiple episode patients might be associ-
ated with progressive neurobiological alterations. The
differences in treatment response between ﬁrst epi-
sode and multiple episode patients should be consid-
ered in the analysis and interpretation of clinical trials
comparing antipsychotic drugs.
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